EMBO Molecular Medicine · 2021 · 20 citations · 49 references
MedicineImmunologyOncologyImmunotherapyMolecular OncologyTumor ImmunologyCancer ImmunotherapyImmune Checkpoint InhibitorsImmune EvasionImmune Evasion In CancerOvarian CancerTumor ImmunopathologyImmune Checkpoint EvasionImmune Evasion By TumorsImmunotherapy For Ovarian CancerOncogenic Immune Evasion PathwaysOvarian Cancer ImmunologyPd-l1 BlockadeProgrammed Death-ligand 1 InhibitorsProgrammed Death-ligand 1 Signaling
Lack of effective immune infiltration represents a significant barrier to immunotherapy in solid tumors. Thus, solid tumor-enriched death receptor-5 (DR5) activating antibodies, which generates tumor debulking by extrinsic apoptotic cytotoxicity, remains a crucial alternate therapeutic strategy. Over past few decades, many DR5 antibodies moved to clinical trials after successfully controlling tumors in immunodeficient tumor xenografts. However, DR5 antibodies failed to significantly improve survival in phase-II trials, leading in efforts to generate second generation of DR5 agonists to supersize apoptotic cytotoxicity in tumors. Here we have discovered that clinical DR5 antibodies activate an unexpected immunosuppressive PD-L1 stabilization pathway, which potentially had contributed to their limited success in clinics. The DR5 agonist stimulated caspase-8 signaling not only activates ROCK1 but also undermines proteasome function, both of which contributes to increased PD-L1 stability on tumor cell surface. Targeting DR5-ROCK1-PD-L1 axis markedly increases immune effector T-cell function, promotes tumor regression, and improves overall survival in animal models. These insights have identified a potential clinically viable combinatorial strategy to revive solid cancer immunotherapy using death receptor agonism.
49
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine · 2018 · 4.4K citations · Full text
Medicine, Oncology, Pharmacology +17
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obéid, Antoine Tesnière, François Ghiringhelli et al. · Nature Medicine · 2006 · 3.1K citations
Medicine, Immunology, Oncology +14
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen, Alexander C. Huang, Wei Zhang et al. · Nature · 2018 · 2.8K citations · Full text
Life Sciences, Immunology, Oncology +14
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Marian L. Burr, Christina E. Sparbier, Yih-Chih Chan et al. · Nature · 2017 · 950 citations · Full text
Medicine, Immunology, Oncology +12